Budesonide oral suspension (Dr Falk Pharma)

N/A

Report date: 2025/07/17 10:38:32

Base Information

Drug NameBudesonide oral suspension (Dr Falk Pharma)
Drug Alias NameJorveza
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonists
TargetsGlucocorticoid receptor
Therapy Area/IndicationsGraft vs Host DiseaseHepatitis, AutoimmuneProctitis +[8] 
Global Approved IndicationsEsophageal Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2018/01/08
Country/TerritorySwedenGermanyIsrael +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDr Falk Pharma GmbH
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Kangzhe Biotechnology Co LtdDr Falk Pharma GmbHLosan Pharma Gmbh
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseEsophageal Diseases
Inactive IndicationsGraft vs Host DiseaseHepatitis, AutoimmuneProctitis +[6] 

Other Information

ATC CodeN/A
Related LinksN/A